BRIEF—Acacia Pharma secures $30 million funding

Acacia Pharma has secured a loan of $30 million from Hercules Technology Growth Capital Inc (Hercules) to support the American launch of its nausea and vomiting therapy Barhemsys (amisulpride).

The drug, which specifically addresses post-operative nausea and vomiting, is due to receieve its Food and Drug Administration verdict in early October.

Christine Soden, head of finance at Acacia, said: "The proceeds from this credit facility provide Acacia with additional funding to support our commercialization activities in the USA as we continue to prepare for the launch, if approved, of Barhemsys."

"We appreciate the support of Hercules, and its confidence in Barhemsys and our management team and look forward to a long and productive working relationship."